Vantia Therapeutics – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 6 PAGES: 32

More Info
									    Vantia Therapeutics – Product Pipeline Review – H2
                           2011
                                                                                          Reference Code: GMDHC01927CDB

                                                                                                 Publication Date: NOV 2011




Vantia Therapeutics – Product Pipeline Review – H2 2011                                     GMDHC01927CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Vantia Therapeutics – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                      2
List of Tables                                                                                                         3
List of Figures                                                                                                        4
Vantia Therapeutics Snapshot                                                                                           5
    Vantia Therapeutics Overview                                                                                       5
    Key Information                                                                                                    5
    Key Facts                                                                                                          5
Vantia Therapeutics – Research and Development Overview                                                                6
    Key Therapeutic Areas                                                                                              6
Vantia Therapeutics – Pipeline Review                                                                                  8
    Pipeline Products by Stage of Development                                                                          8
    Vantia Therapeutics – Pipeline Products Glance                                                                     9
    Vantia Therapeutics Clinical Stage Pipeline Products                                                               9
         Phase II Products/Combination Treatment Modalities                                                            9
         Phase I Products/Combination Treatment Modalities                                                            10
    Vantia Therapeutics–Early Stage Pipeline Products                                                                 11
         Pre-Clinical Products/Combination Treatment Modalities                                                       11
Vantia Therapeutics – Drug Profiles                                                                                   12
    FAP Inhibitor For Oncology and Fibrosis                                                                           12
         Product Description                                                                                          12
         Mechanism of Action                                                                                          12
         R&D Progress                                                                                                 12
    KLK1 Inhibitor For Inflammatory Diseases                                                                          13
         Product Description                                                                                          13
         Mechanism of Action                                                                                          13
         R&D Progress                                                                                                 13
    VA106483                                                                                                          14
         Product Description                                                                                          14
         Mechanism of Action                                                                                          14
         R&D Progress                                                                                                 14
    VA111913                                                                                                          15
         Product Description                                                                                          15
         Mechanism of Action                                                                                          15
         R&D Progress                                                                                                 15
    VA118020                                                                                                          16
         Product Description                                                                                          16
         Mechanism of Action                                                                                          16
         R&D Progress                                                                                                 16
    VA999260                                                                                                          17
         Product Description                                                                                          17
         Mechanism of Action                                                                                          17
         R&D Progress                                                                                                 17
Vantia Therapeutics – Pipeline Analysis                                                                               18
    Vantia Therapeutics – Pipeline Products by Therapeutic Class                                                      18
    Vantia Therapeutics - Pipeline Products By Target                                                                 19
    Vantia Therapeutics – Pipeline Products by Route of Administration                                                20




Vantia Therapeutics – Product Pipeline Review – H2 2011                                   GMDHC01927CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                              Page(2)
Vantia Therapeutics – Product Pipeline Review



    Vantia Therapeutics – Pipeline Products by Molecule Type                                                                                 21
Vantia Therapeutics - Dormant Projects                                                                                                       22
Vantia Therapeutics – Locations And Subsidiaries                                                                                             23
    Head Office                                                                                                                              23
Recent Developments                                                                                                                          24
         Jun 29, 2009: Vantia Therapeutics’ Lead Candidate VA106483 Demonstrates Positive Anti-Diuretic Effect In Phase IIa Trial In Nocturia 24
         Mar 26, 2010: Vantia Therapeutics Reveals Structure Of Its Novel Small Molecule Treatment For Dysmenorrhoea, VA111913               24
         Mar 24, 2009: Vantia Therapeutics' VA106483 Completes Phase IIa Trial                                                               25
         Mar 24, 2009: Vantia Therapeutics' VA111913 Completes Phase I Dosing                                                                26
         Mar 23, 2009: Vantia Therapeutics Pipeline Continues To Mature                                                                      26
         Oct 06, 2009: Vantia Therapeutics’ VA111913 Enters Phase II Proof---Of---Concept Trials For Dysmenorrhoea                           27
         Feb 02, 2010: Vantia Therapeutics Initiates Phase IIb Clinical Trial Of VA106483 For Nocturia                                       27
Financial Deals Landscape                                                                                                                    28
    Vantia Therapeutics, Deals Summary                                                                                                       28
Vantia Therapeutics, Pharmaceuticals & Healthcare, Deal Details                                                                              29
    Venture Financing                                                                                                                        29
         Vantia Therapeutics Secures $6.5 Million In Series B Financing                                                                      29
Appendix                                                                                                                                     31
    Methodology                                                                                                                              31
         Coverage                                                                                                                            31
         Secondary Research                                                                     
								
To top